Carregant...

Memantine: efficacy and safety in mild-to-severe Alzheimer’s disease

Alzheimer’s disease (AD) is the most common cause of dementia, accounting for 25 million cases worldwide. Until recently, the pharmacotherapy of AD was limited to the use of cholinesterase inhibitors (ChEIs) that are approved only for the mild to moderate stages of the illness. Memantine, an NMDA re...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Tampi, Rajesh R, van Dyck, Christopher H
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2007
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2654628/
https://ncbi.nlm.nih.gov/pubmed/19300557
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!